Novel thienopyrimidinones as mGluR1 antagonists

Youngjae Kim; Jeeyeon Kim; Sora Kim; Yooran Ki; Seon Hee Seo; Jinsung Tae; Min Kyung Ko; Hyun Seo Jang; Eun Jeong Lim; Chiman Song; Yoonjeong Cho; Hae Young Koh; Youhoon Chong; Il Han Choo; Gyochang Keum; Sun Joon Min; Hyunah Choo

doi:10.1016/j.ejmech.2014.08.027

Novel thienopyrimidinones as mGluR1 antagonists

Youngjae Kim, Jeeyeon Kim, Sora Kim, Yooran Ki, Seon Hee Seo, Jinsung Tae, Min Kyung Ko, Hyun Seo Jang, Eun Jeong Lim, Chiman Song, Yoonjeong Cho, Hae Young Koh, Youhoon Chong, Il Han Choo, Gyochang Keum, Sun Joon Min, Hyunah Choo

Department of Chemistry

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

There has been much attention to discover mGluR1 antagonists for treating various central nervous system diseases such as seizures and neuropathic pain. Thienopyrimidinone derivatives were designed, synthesized, and biologically evaluated against mGluR1. Among the synthesized compounds, 3-(4-methoxyphenyl)- 7-(o-tolyl)thienopyrimidin-4-one 30 exhibited the most potent inhibitory activity with an IC₅₀ value of 45 nM and good selectivity over mGluR5. Also, the selective mGluR1 antagonist 30 showed marginal hERG channel activity (IC₅₀ = 9.87 μM), good profiles to CYP isozymes, and a good pharmacokinetic profile. Overall, the compound 30 was identified as a selective mGluR1 antagonist with a good pharmacokinetic profile, which is probably devoid of cardiac side effect and drug-drug interactions. Therefore, the compound 30 can be expected to be broadly used as mGluR1 antagonistic chemical probe in in vitro and in vivo study for investigating CNS diseases.

Original language	English
Pages (from-to)	629-637
Number of pages	9
Journal	European Journal of Medicinal Chemistry
Volume	85
DOIs	https://doi.org/10.1016/j.ejmech.2014.08.027
Publication status	Published - 2014 Oct 6

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program ( NRF-2013-R1A1A2A10009907 ) and the Priority Research Centers Program ( 2009-0093824 ) funded by the National Research Foundation of Korea (NRF) and a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea ( HI11C0998 ). Additional funding was provided by the Korea Institute of Science and Technology (KIST) Institutional Program ( 2E24510 and 2E24670 ).

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery
Organic Chemistry

Access to Document

10.1016/j.ejmech.2014.08.027

Fingerprint Dive into the research topics of 'Novel thienopyrimidinones as mGluR1 antagonists'. Together they form a unique fingerprint.

Cite this

Kim, Youngjae ; Kim, Jeeyeon ; Kim, Sora ; Ki, Yooran ; Seo, Seon Hee ; Tae, Jinsung ; Ko, Min Kyung ; Jang, Hyun Seo ; Lim, Eun Jeong ; Song, Chiman ; Cho, Yoonjeong ; Koh, Hae Young ; Chong, Youhoon ; Choo, Il Han ; Keum, Gyochang ; Min, Sun Joon ; Choo, Hyunah. / Novel thienopyrimidinones as mGluR1 antagonists. In: European Journal of Medicinal Chemistry. 2014 ; Vol. 85. pp. 629-637.

@article{d97f4ec359f64015bc4b08cc01904cdc,

title = "Novel thienopyrimidinones as mGluR1 antagonists",

abstract = "There has been much attention to discover mGluR1 antagonists for treating various central nervous system diseases such as seizures and neuropathic pain. Thienopyrimidinone derivatives were designed, synthesized, and biologically evaluated against mGluR1. Among the synthesized compounds, 3-(4-methoxyphenyl)- 7-(o-tolyl)thienopyrimidin-4-one 30 exhibited the most potent inhibitory activity with an IC50 value of 45 nM and good selectivity over mGluR5. Also, the selective mGluR1 antagonist 30 showed marginal hERG channel activity (IC50 = 9.87 μM), good profiles to CYP isozymes, and a good pharmacokinetic profile. Overall, the compound 30 was identified as a selective mGluR1 antagonist with a good pharmacokinetic profile, which is probably devoid of cardiac side effect and drug-drug interactions. Therefore, the compound 30 can be expected to be broadly used as mGluR1 antagonistic chemical probe in in vitro and in vivo study for investigating CNS diseases.",

author = "Youngjae Kim and Jeeyeon Kim and Sora Kim and Yooran Ki and Seo, {Seon Hee} and Jinsung Tae and Ko, {Min Kyung} and Jang, {Hyun Seo} and Lim, {Eun Jeong} and Chiman Song and Yoonjeong Cho and Koh, {Hae Young} and Youhoon Chong and Choo, {Il Han} and Gyochang Keum and Min, {Sun Joon} and Hyunah Choo",

note = "Funding Information: This research was supported by the Basic Science Research Program ( NRF-2013-R1A1A2A10009907 ) and the Priority Research Centers Program ( 2009-0093824 ) funded by the National Research Foundation of Korea (NRF) and a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea ( HI11C0998 ). Additional funding was provided by the Korea Institute of Science and Technology (KIST) Institutional Program ( 2E24510 and 2E24670 ). ",

year = "2014",

month = oct,

day = "6",

doi = "10.1016/j.ejmech.2014.08.027",

language = "English",

volume = "85",

pages = "629--637",

journal = "European Journal of Medicinal Chemistry",

issn = "0223-5234",

publisher = "Elsevier Masson SAS",

}

Novel thienopyrimidinones as mGluR1 antagonists. / Kim, Youngjae; Kim, Jeeyeon; Kim, Sora; Ki, Yooran; Seo, Seon Hee; Tae, Jinsung; Ko, Min Kyung; Jang, Hyun Seo; Lim, Eun Jeong; Song, Chiman; Cho, Yoonjeong; Koh, Hae Young; Chong, Youhoon; Choo, Il Han; Keum, Gyochang; Min, Sun Joon; Choo, Hyunah.

In: European Journal of Medicinal Chemistry, Vol. 85, 06.10.2014, p. 629-637.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Novel thienopyrimidinones as mGluR1 antagonists

AU - Kim, Youngjae

AU - Kim, Jeeyeon

AU - Kim, Sora

AU - Ki, Yooran

AU - Seo, Seon Hee

AU - Tae, Jinsung

AU - Ko, Min Kyung

AU - Jang, Hyun Seo

AU - Lim, Eun Jeong

AU - Song, Chiman

AU - Cho, Yoonjeong

AU - Koh, Hae Young

AU - Chong, Youhoon

AU - Choo, Il Han

AU - Keum, Gyochang

AU - Min, Sun Joon

AU - Choo, Hyunah

N1 - Funding Information: This research was supported by the Basic Science Research Program ( NRF-2013-R1A1A2A10009907 ) and the Priority Research Centers Program ( 2009-0093824 ) funded by the National Research Foundation of Korea (NRF) and a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea ( HI11C0998 ). Additional funding was provided by the Korea Institute of Science and Technology (KIST) Institutional Program ( 2E24510 and 2E24670 ).

PY - 2014/10/6

Y1 - 2014/10/6

N2 - There has been much attention to discover mGluR1 antagonists for treating various central nervous system diseases such as seizures and neuropathic pain. Thienopyrimidinone derivatives were designed, synthesized, and biologically evaluated against mGluR1. Among the synthesized compounds, 3-(4-methoxyphenyl)- 7-(o-tolyl)thienopyrimidin-4-one 30 exhibited the most potent inhibitory activity with an IC50 value of 45 nM and good selectivity over mGluR5. Also, the selective mGluR1 antagonist 30 showed marginal hERG channel activity (IC50 = 9.87 μM), good profiles to CYP isozymes, and a good pharmacokinetic profile. Overall, the compound 30 was identified as a selective mGluR1 antagonist with a good pharmacokinetic profile, which is probably devoid of cardiac side effect and drug-drug interactions. Therefore, the compound 30 can be expected to be broadly used as mGluR1 antagonistic chemical probe in in vitro and in vivo study for investigating CNS diseases.

AB - There has been much attention to discover mGluR1 antagonists for treating various central nervous system diseases such as seizures and neuropathic pain. Thienopyrimidinone derivatives were designed, synthesized, and biologically evaluated against mGluR1. Among the synthesized compounds, 3-(4-methoxyphenyl)- 7-(o-tolyl)thienopyrimidin-4-one 30 exhibited the most potent inhibitory activity with an IC50 value of 45 nM and good selectivity over mGluR5. Also, the selective mGluR1 antagonist 30 showed marginal hERG channel activity (IC50 = 9.87 μM), good profiles to CYP isozymes, and a good pharmacokinetic profile. Overall, the compound 30 was identified as a selective mGluR1 antagonist with a good pharmacokinetic profile, which is probably devoid of cardiac side effect and drug-drug interactions. Therefore, the compound 30 can be expected to be broadly used as mGluR1 antagonistic chemical probe in in vitro and in vivo study for investigating CNS diseases.

UR - http://www.scopus.com/inward/record.url?scp=84906079450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906079450&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2014.08.027

DO - 10.1016/j.ejmech.2014.08.027

M3 - Article

C2 - 25127154

AN - SCOPUS:84906079450

VL - 85

SP - 629

EP - 637

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -